Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118326 · ClinicalTrials.gov registry record · Phase 1
Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00118326 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center.
The verdict
NCT00118326, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: A bone marrow transplant from a brother or sister may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. Colony-stimulating factors, such as G-CSF, cause the body to make blood cells. Giving G-CSF to the donor may help the body make more stem cells that can be collected for bone marrow transplant and may cause fewer side effects in the patient after the transplant. PURPOSE: This phase I/II trial is studying the side effects of donor bone marrow transplant and to see how well it works in treating young patients with cancer or a non-cancerous disease.
Interventions
- BIOLOGICAL filgrastim
- PROCEDURE allogeneic bone marrow transplantation
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-08 |
| Est. Completion | 2007-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00118326
The ClinicalTrials.gov registry entry for NCT00118326 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which filgrastim is the first listed.
NCT00118326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00118326 about?
NCT00118326 is a clinical study titled "Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease". RATIONALE: A bone marrow transplant from a brother or sister may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. Colony-stimulating factors, such as G-CSF, cause the body to make blood cells. Giving G-CSF to the donor may help the body make more stem ...
What is the current status of trial NCT00118326?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-08. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00118326?
The interventions under investigation include: filgrastim (BIOLOGICAL), allogeneic bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00118326?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.